COVID-19 UPDATE: All elective surgeries and procedures have been postponed. See our visitor policy. If you think you have symptoms, call your doctor for a video visit before going to one of our locations. For more information, visit our COVID-19 Information Center or call our Hotline: 1-844-444-CV19 (1-844-444-2819).

AVISO SOBRE COVID-19: Todas las cirugías y procedimientos electivos han sido retrasados. Vea nuestra normas para visitas. Si cree que tiene síntomas, llame a su médico para una visita por vídeo antes de acudir en persona a uno de nuestros centros. Si desea más información, por favor visite nuestro Centro de Información del COVID-19 o llame a nuestra Línea Directa: 1-844-444-CV19 (1-844-444-2819).

Espanol
Hematology Oncology Fellowship
Home >  Cancer (Oncology) >  Education >  Hematology Oncology Fellowship
Print

Education

Hematology/Oncology Fellowship



Current fellows, 2015 graduate fellows and faculty

The Hematology Oncology Fellowship at Montefiore Medical Center and Albert Einstein College of Medicine provides comprehensive training in clinical practice, clinical investigation, and laboratory science. Established in 1959, our three and four-year programs offer an exceptional range of experience and research opportunities to fully prepare physicians for academic and clinical practice in hematology/oncology.

Our ACGME accredited fellowship program sponsors ten new fellows each year and includes rotations at Montefiore Medical Center, and Jacobi Medical Center. Under the guidance of a staff of 48 hematology and oncology faculty members, including clinicians, scientists, and research scientists, fellows receive a thorough education in benign and malignant hematology, oncology, immunology and bone marrow transplantation. Fellows are responsible for consultations and ongoing care of inpatients and outpatients.

Because we serve a population of more than 1.6 million residents in the New York Metropolitan area, fellows are exposed to diverse cultures and a broad spectrum of hematologic and oncologic disorders. Our fellows consider multi-tiered diagnoses, ranging from various rare carcinomas to sickle cell disease. Fellows perform various types of hematopoietic stem cell transplants; perform oncological gynecologic consults, hematological obstetric evaluations and see solid tumor and oncologic/hematologic solid organ/ hematopoietic stem transplant related complications.

The fellowship experience is constructed with a stronger emphasis on clinical hematology and oncology research than that of many other institutions. Working closely with one of our clinical investigators, fellows receive formal instruction on creating, executing, and interpreting clinical trials pertaining to thrombosis, hemoglobinopathy, hematological malignancies, Hematopoetic stem cells, and phase 1 studies, breast, gastrointestinal, genitourinary and lung malignancies. Numerous unique educational and research opportunities are available to fellows, such as participating in twice a month research conferences as well as disease specific tumor boards. Tumor Boards consisting of specialists from Surgery, Medical Oncology, Medical Specialties including interventional pulmonologist,  and gastroenterologist, Radiation Oncology, Radiology and Pathology form the centerpiece of the oncology-teaching program, as they evaluate and discuss patients for whom a multidisciplinary approach is being considered. A formal curriculum dealing with ethical, medicolegal, and socioeconomic issues is also integrated into the program.

Fellows fulfill 18 months of clinical rotations, with ample options to customize their individual training path in the second and third years under the guidance of a mentor. They can participate in basic science, molecular translational studies and clinical hematology and oncology research. Areas of interest in our institution include: colon cancer (basic molecular oncology, new prevention strategies and therapies), breast and lung cancer, phase 1 studies, antiphospholipd syndrome, hemoglobinopathy, stem cell biology, TTP, von Willebrand's disease, red cell